Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?

The stock has declined 5.9% year to date, lower than the industry's 8.8% fall. In comparison, peers GE Healthcare (GEHC) and Becton, Dickinson and Company (BDX) have seen steeper declines. Hologic's YTD Performance Image Source: Zacks Investment Research Hologic's Q3: A Quick Recap The company posted revenues of $1.02 billion and adjusted earnings per share (EPS) of $1.08, both surpassing the respective Zacks Consensus Estimate. The Molecular Diagnostics business led the way, with U.S. sales climbing 7.3% o ...